Biology-oriented drug synthesis (BIODS): In vitro β-glucuronidase inhibitory and in silico studies on 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl aryl carboxylate derivatives
详细信息 查看全文
- 作者：Uzma Salar<sup>asup> ; Khalid Mohammed Khan<sup>asup><sup> ; sup><sup>khalid.khan@iccs.edusup><sup> ; sup><sup>hassaan2@super.net.pksup> ; Muhammad Taha<sup>bsup><sup> ; sup><sup>csup> ; Nor Hadiani Ismail<sup>bsup> ; Basharat Ali<sup>asup> ; Qurat-ul-Ain<sup>asup> ; Shahnaz Perveen<sup>dsup> ; Mehreen Ghufran<sup>esup> ; Abdul Wadood<sup>esup>
- 关键词：Synthesis ; In vitro ; β-Glucuronidase ; In silico ; Structure-activity relationship
- 刊名：European Journal of Medicinal Chemistry
- 出版年：2017
- 出版时间：5 January 2017
- 年：2017
- 卷：125
- 期：Complete
- 页码：1289-1299
- 全文大小：2184 K
- 卷排序：125
文摘
Biology-oriented drug synthesis (BIODS) of 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl aryl carboxylate derivatives 1–26. All compounds were evaluated for in vitro β-glucuronidase inhibitory activity. Except few derivatives, all molecules were demonstrated good inhibition. Molecular docking studies were carried out to verify the structure-activity relationship.